drugset / Trial / NCT02370524

Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease

NCT02370524

NaSingle-groupOpen-labelOther

Summary

The primary objective of this exploratory imaging study is to further characterize \[18F\]T807, an investigational PET radioligand for imaging Tau (thought to be a downstream biomarker indicative of neurodegeneration in conditions such as AD).

Timeline

Start
2015-01
Primary completion
2016-01
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Subject florbetapir F 18 Diagnostic / imaging agent 370 mbq

Indications